Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-11-10
2010-02-16
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120
Reexamination Certificate
active
07662579
ABSTRACT:
The invention provides methods and materials for determining a prognosis for myeloma and myeloma-disposed patients. The methods include the use of FISH techniques. The identification of the chromosomal abnormalities t(4;14)(p16;q32), t(14;16)(q32;q23), or 17p13 deletion (p53) in plasma cells from a patient indicates a poor prognosis.
REFERENCES:
Könisberg et al, J Clin Oncol, 2000, 18:804-812.
Bergsagel et al, PNAS, 1996, 93:13931-13936.
Ahmann et al, Cancer Genet Cytogenet, 1998, 101:7-11.
Avet-Loiseau et al, Cancer Res, 1998, 58:5640-5645.
Ackermann et al., “Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undedetermined significance,” Br. J. Haematol., 103:1161-1163 (1998).
Avet-Loiseau et al., “P53 deletion is not a frequent event in multiple myeloma,” Br. J. Haematol., 106:717-719 (1999).
Avet-Loiseau et al., “14q32 Translocations and Monosomy 13 Observed in Monoclonal Gammopathy of Undetermined Significance Delineate a Multistep Process for the Oncogenesis of Multiple Myeloma,” Cancer Res., 59:4546-4550 (1999).
Avet-Loiseau et al., “High Incidence of Cryptic Translocations Involving the Ig Heavy Chain Gene in Multiple Myeloma, as Shown by Fluorescence in Situ Hybridization,” Genes Chromosomes Cancer, 24:9-15 (1999).
Avet-Loiseau et al., “Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13,” Br. J. Haematol., 111:1116-1117 (2000).
Chesi et al., “Dysregulation of Cyclin D1 by Translocation Int an IgH Gamma Switch Region in Two Multiple Myeloma Cell Lines,” Blood, 88:674-681 (1996).
Chesi et al., “Frequent Dysregulation of the c-mafProto-Oncogene at 16q23 by Translocation to an Ig Locus in Multiple Myeloma,” Blood, 91:4457-4463 (1998).
Chesi et al., “The t(4;14) Translocation in Myeloma Dysregulates BothFGFR3and a Novel Gene,MMSET, Resulting in IGH/MMSET Hybrid Transcripts,” Blood, 92:3025-3034 (1998).
Corradini et al., “Inactivation of Tumor Suppressor Genes, p53 and Rb1, in Plasma Cell Dyscrasias,” Leukemia, 8:758-767 (1994).
Dewald et al., “The Clinical Significance of Cytogenetic Studies in 100 Patients With Multiple Myeloma, Plasma Cell Leukemia, or Amyloidosis,” Blood, 66:380-390 (1985).
Drach et al., “Presence of a p53 Gene Deletion in Patients with Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy,” Blood, 92:802-809 (1998).
Drach et al., “‘Blood Doping’ With Recombinant Erythropoietin (rhEPO) and Assessment of Functional Iron Deficiency in Healthy Volunteers,” Br. J. Haematol., 108:883-886 (2000).
Facon et al., “Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy,” Blood, 97:1566-1571 (2001).
Finelli et al., “Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Double-Color Fluorescent in Situ Hybridization,” Blood, 94:724-732 (1999).
Fonseca, et al., “Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases,” Br. J. Haematol., 101:296-301 (1998).
Fonseca et al., “The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance,” Blood, 98:1271-1272 (2001).
Fonseca et al., “Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy,” Leukemia, 15:981-986 (2001).
Fonseca et al., “Genomic abnormalities in monoclonal gammopathy of undetermined significance,” Blood, 100:1417-1424 (2002).
Fonseca et al., “Biological and Prognostic Significance of Interphase Fluorescence in Situ Hybridization Detection of Chromosome 13 Abnormalities (Δ13) in Multiple Myeloma: An Eastern Cooperative Oncology Group Study,” Cancer Res., 62:715-720 (2002).
Fonseca et al., “Myeloma and the t(11;14)(q13;132); evidence for a biologically defined unique subset of patients,” Blood, 99:3735-3741 (2002).
Hayman et al., “Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis,” Blood, 98:2266-2268 (2001).
Janssen et al., “Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32),” Blood, 95:2691-2698 (2000).
Moreau et al., “Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy,” Blood, 100:1579-1583 (2002).
“Multiple Myeloma: a Disease Overview,” New Canaan, CT: Multiple Myeloma Research Foundation (2001).
Neri et al., “p53 Gene Mutations in Multiple Myeloma Are Associated With Advanced Forms of Malignancy,” Blood, 81:128-135 (1993).
Perfetti et al., “Translocation t(4;14)(p16.3;q32) Is a Recurrent Genetic Lesion in Primary Amyloidosis,” Am. J. Pathol., 158:1599-1603 (2001).
Richelda et al., “A Novel Chromosomal Translocation t(4;14)(p16.3;q32) in Multiple Myeloma Involves the Fibroblast Growth-Factor Receptor 3 Gene,” Blood, 90:4062-4070 (1997).
Schreiber et al., “Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization,” Br. J. Haematol., 110:605-609 (2000).
Shaughnessy Jr., et al., “High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH,” Blood, 96:1505-1511 (2000).
Shaughnessy Jr., et al., “Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma,” Blood, 98:217-223 (2001).
Shou, et al., “Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma,” PNAS, 97:228-233 (2000).
Zojer et al., “Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization,” Blood, 95:1925-1930 (2000).
Avet-Loiseau et al., “High Incidence of Translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in Patients with Plasma Cell Malignancies,”Cancer Research58:5640-5645 (1998).
Chesi et al., “Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3,”Nature Genetics16:260-264 (1997).
Mazars et al., “Mutations of the p53 gene in human myeloma cell lines,”Oncogene7:1015-1018 (1992).
Preudhomme et al., “Rare occurrence of P53 gene mutations in multiple myeloma,”British J. of Hematology81:440-443 (1992).
Harrison et al. “Chromosomal Abnormalities in Systemic AL Amyloidosis” VIII Int'l Myeloma Workshop, Banff, Alberta, Canada, p. 18 (2001).
Avet-Loiseau et al., “A Comprehensive FISH Analysis Identifies Myeloma Patient Subgroups with Different Outcome,” American Society of Hematology Annual Meeting (43rd; Dec. 2001; Florida, USA); abstract published on-line Nov. 16, 2001.
Fonseca et al., “A Molecular Classification of Multiple Myeloma (MM), Based on Cytogenetic Abnormalities Detected by Interphase FISH, is Powerful in Identifying Discrete Groups of Patients with Sissimilar Prognosis,” American Society of Hematology Annual Meeting (43rd; Dec. 2001; Florida, USA); abstract published on-line Nov. 16, 2001.
Fonseca et al., “Clinical and biologic implications of recurrent genomic aberrations in myeloma,”Blood101:4569-4575, 2003.
Fonseca Rafael
Greipp Philip R.
Fish & Richardson P.C.
Halvorson Mark
Mayo Foundation for Medical Education and Research
Yu Misook
LandOfFree
Cytogenetically determined prognosis of myeloma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytogenetically determined prognosis of myeloma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytogenetically determined prognosis of myeloma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4177436